These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Postsynaptic supersensitivity in schizophrenia. Pandey GN; Garver DL; Tamminga C; Ericksen S; Ali SI; Davis JM Am J Psychiatry; 1977 May; 134(5):518-22. PubMed ID: 848578 [TBL] [Abstract][Full Text] [Related]
44. Schneider's first-rank symptoms of schizophrenia: prevalence and diagnostic use. A study from Pakistan. Malik SB; Ahmed M; Bashir A; Choudhry TM Br J Psychiatry; 1990 Jan; 156():109-11. PubMed ID: 2297605 [TBL] [Abstract][Full Text] [Related]
45. Diagnostic valve of Schneider's first rank symptoms in schizophrenia. Chopra HD; Gunter M Br J Psychiatry; 1987 Jan; 150():132. PubMed ID: 3651667 [No Abstract] [Full Text] [Related]
46. Disintegration of the components of language as the path to a revision of Bleuler's and Schneider's concepts of schizophrenia. Linguistic disturbances compared with first-rank symptoms in acute psychosis. Ceccherini-Nelli A; Crow TJ Br J Psychiatry; 2003 Mar; 182():233-40. PubMed ID: 12611787 [TBL] [Abstract][Full Text] [Related]
47. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia. Nair NP; Lal S; Cervantes P; Yassa R; Guyda H Neuropsychobiology; 1979; 5(3):136-42. PubMed ID: 431802 [TBL] [Abstract][Full Text] [Related]
48. Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients. Müller-Spahn F; Modell S; Ackenheil M; Brachner A; Kurtz G J Psychiatr Res; 1998; 32(5):265-71. PubMed ID: 9789204 [TBL] [Abstract][Full Text] [Related]
49. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats. Mueller GP; Simpkins J; Meites J; Moore KE Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594 [TBL] [Abstract][Full Text] [Related]
51. Growth hormone response to clonidine in neuroleptic-free patients with multidagnostically defined schizophrenia. Keks NA; Copolov DL; McKenzie DP; Kulkarni J; Hassett A; Matheson B; Hill C; Mackie B; Singh B; Hirt J Psychiatry Res; 1993 Jul; 48(1):79-90. PubMed ID: 8416019 [TBL] [Abstract][Full Text] [Related]
52. Are there pathognomonic symptoms in schizophrenia? An empiric investigation of Schneider's first-rank symptoms. Carpenter WT; Strauss JS; Muleh S Arch Gen Psychiatry; 1973 Jun; 28(6):847-52. PubMed ID: 4707991 [No Abstract] [Full Text] [Related]
53. A study of Schneider's first-rank symptoms of schizophrenia in Nigerian patients. Gureje O; Bamgboye EA Br J Psychiatry; 1987 Jun; 150():867-9. PubMed ID: 3651746 [TBL] [Abstract][Full Text] [Related]
55. Frequency of occurrence of Schneider's first rank symptoms in Schizophrenia. Marneros A Eur Arch Psychiatry Neurol Sci; 1984; 234(1):78-82. PubMed ID: 6489400 [TBL] [Abstract][Full Text] [Related]
56. Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease. Durso R; Tamminga CA; Denaro A; Ruggeri S; Chase TN Neurology; 1983 Sep; 33(9):1229-32. PubMed ID: 6225034 [TBL] [Abstract][Full Text] [Related]
57. Schneider's first rank symptoms: a review. Chandrasena R Psychiatr J Univ Ott; 1983 Jun; 8(2):86-95. PubMed ID: 6351144 [No Abstract] [Full Text] [Related]